Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non –small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2

CONCLUSIONSAll 3 regimens were feasible for patients with advanced NSCLC and an ECOG performance status of 2. The addition of bevacizumab to pemetrexed increased the overall response rate. The efficacy of pemetrexed/carboplatin/bevacizumab (median PFS, 4.8 months) approached the prespecified study PFS goal of 5 months. Larger studies will be necessary to define the role of bevacizumab in addition to standard pemetrexed and carboplatin in this population. Cancer 2018. © 2018 American Cancer Society.

Source: Cancer - February 16, 2018 Category: Cancer & Oncology Authors: David R. Spigel, John D. Hainsworth, Mathew J. Joseph, Dianna L. Shipley, M. Kelly Hagan, Dana S. Thompson, Howard A. Burris, F. Anthony Greco Tags: Original Article Source Type: research